Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT

Christian Gisselbrecht • 31 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Cisplatin Cytarabine Rituximab
CORAL LY.12

Christian Gisselbrecht, MD, Saint-Louis Hospital, Paris, France, discusses long-term survival after 2 year’s event-free survival in relapsed diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplantation (ASCT) in the two randomized trials LY.12 (NCT00078949) and CORAL (NCT00137995). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christian Gisselbrecht

2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
2:38
ZUMA-1 & SCHOLAR-1: comparison of outcomes in refractory DLBCL
Christian Gisselbrecht • 31 Aug 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals